Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer?
- PMID: 37782311
- DOI: 10.1158/1078-0432.CCR-23-1909
Can We De-escalate Therapy for HER2-Positive Metastatic Breast Cancer?
Abstract
A recent phase Ib/II trial evaluated the combination of tucatinib, letrozole, and palbociclib in patients with HR+/HER2+ metastatic breast cancer, demonstrating a manageable safety profile and encouraging efficacy data. An all-oral, chemotherapy-free regimen is an appealing strategy, and could be a possible maintenance or primary therapy option in select patients. See related article by Shagisultanova et al., p. 5021.
©2023 American Association for Cancer Research.
Comment on
-
Safety and Efficacy of Tucatinib, Letrozole, and Palbociclib in Patients with Previously Treated HR+/HER2+ Breast Cancer.Clin Cancer Res. 2023 Dec 15;29(24):5021-5030. doi: 10.1158/1078-0432.CCR-23-0117. Clin Cancer Res. 2023. PMID: 37363965 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous